ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2308

Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis

AUGUSTA ORTOLAN1, Désirée Van Der Heijde2, Laure Gossec3 and Sofia Ramiro4, 1Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 4Leiden University Medical Center, Bunde, Netherlands

Meeting: ACR Convergence 2025

Keywords: Disease Activity, functional status, Outcome measures, quality of life, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Health-related quality of life (HRQoL) is an overarching outcome in axial spondyloarthritis (axSpA), and is considered influenced by disease activity and physical function. However, this relationship has never been demonstrated in a longitudinal framework. The impact of disease activity on HRQoL may be either direct, or occur indirectly by worsening physical function. The aim of this study was to investigate whether the effect of disease activity on HRQoL is primarily direct or mediated by physical function over time in early axSpA.

Methods: AxSpA patients from the DESIR cohort were analysed over 10 years of follow-up. Disease activity (assessed by the Ankylosing Spondylitis Disease Activity Score, ASDAS), physical function (Bath Ankylosing Spondylitis Functional Index, BASFI), and HRQoL outcomes (Physical Component Summary [PCS] and Mental Component Summary [MCS] of the SF-36, with higher values representing better HRQoL, and Ankylosing Spondylitis Quality of Life [ASQoL], with higher values corresponding to worse HRQoL) were assessed. Structural equation modeling (SEM) was performed to assess mediation, including direct and indirect (i.e. mediated) effects of disease activity on HRQoL. The hypothesis regarding mediation was that ASDAS and BASFI (assessed at the same time point) impact HRQoL at a subsequent time point (ie one year later). All models were adjusted for significant covariates (eg sex, marital/social status, BMI, NSAID use, bDMARDs use, enthesitis, IBD, comorbidity count) .Results are presented as beta coefficient (95% confidence intervals).

Results: A total of 663 patients were analysed, 46% males, mean age 33.5 (8.6) years. At 10 years, both ASDAS and BASFI were on the low range (ASDAS 2.0 [1.0] BASFI 2.3 [2.2]), and QoL scores were moderate at the group level (PCS 42.9 [10.4], MCS 45.0 [10.5], ASQoL 6.5 [5.5]). BASFI significantly mediated the association between ASDAS and HRQoL (Table 1). The indirect effects through BASFI were consistently larger than the direct effects. For PCS, the indirect effect was -3.09 (-3.38,-2.80) and the direct effect was -1.22 (-1.65,-0.80). For MCS, the indirect effect was -2.09 (-2.50,-1.71) versus a direct effect of -1.55 (-2.11,-1.00). For ASQoL, the indirect effect was 1.58 (1.41,1.75) and the direct effect was 0.59 (0.36, 0.82). Despite the majority of the effect of ASDAS on HRQoL being mediated, about a quarter of the effect was direct (Figure 1). These findings confirm HRQoL as a higher-order outcome, supported by its longitudinal association with both ASDAS and BASFI. We then propose a model of disease outcomes in axSpA, with proven longitudinal relationships (Figure 2).

Conclusion: In early axSpA, disease activity impacts HRQoL mainly through its negative influence on physical function; however a direct, independent effect also exists. These findings reinforce the hierarchical model of disease outcomes and emphasize the central role of targeting disease activity to optimize HRQoL, through its direct and indirect effects.

Supporting image 1Table 1. Mediation analysis considering a direct and indirect (mediated by function, BASFI) effect of disease activity (ASDAS) on HRQoL, according to the main mediation hypothesis (ASDAS and BASFI influence HRQoL one year later)

Supporting image 2Figure 1. Mediation structure, with estimation of direct and indirect effects

Legend. t = time point; t+1 = time point plus 1 year

Supporting image 3Figure 2. Longitudinal framework with Health Related Quality of Life as the overarching outcome

Legend. The shadowed blocks represent the main variables of interest for this analysis. Red arrows represent the longitudinal relationships clarified by this current analysis. Blue arrows represent (longitudinal) associations previously described in the literature.


Disclosures: A. ORTOLAN: AbbVie/Abbott, 6, AstraZeneca, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 6; D. Van Der Heijde: AbbVie, 2, Alfasigma, 2, Annals of the Rheumatic Diseases, 12, Associate editor, ArgenX, 2, Bristol Myers Squibb, 2, Eli Lilly and Company, 2, Grey-Wolf Therapeutics, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Journal of Rheumatology, 12, Editorial board member, Novartis, 2, Pfizer, 2, RMD Open, 12, Editoral board member, Takeda, 2, UCB, 2; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, BMS, 2, Celltrion, 2, Eli Lilly, 2, 5, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, UCB, 2, 5; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, 5, Galapagos/Alfasigma, 2, 5, Janssen, 2, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

ORTOLAN A, Van Der Heijde D, Gossec L, Ramiro S. Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/physical-function-mediates-most-but-not-all-of-the-effect-of-disease-activity-on-health-related-quality-of-life-in-axial-spondyloarthritis-a-10-year-longitudinal-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physical-function-mediates-most-but-not-all-of-the-effect-of-disease-activity-on-health-related-quality-of-life-in-axial-spondyloarthritis-a-10-year-longitudinal-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology